TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fugl-Meyer assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Musculoskeletal sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Functional Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or Higher Rate of Non-hematologic Acute Treatment-related Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral pulmonary lesion diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants defining the clinical bottom line
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: knee proprioception at 30 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee proprioception at 45 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee proprioception at 60 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory neuropathies
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Postoperative Pancreatic Fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Serum bone remodelling markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum bone metabolism markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of Gastrointestinal peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Score of Erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Uncorrected Decimal Visual Acuity at 5 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected Decimal Visual Acuity at 50 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected Decimal Visual Acuity at 5 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected Decimal Visual Acuity at 50 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-Corrected Decimal Visual Acuity at 50 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Crohn's Disease Activity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prostatic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side-to-side differences in 3-dimensional scapular angular displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Side-to-side differences in 3-dimensional humerus angular displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Side-to-side differences in 3-dimensional thoracic angular displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Prevalence of chest wall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of Pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Partial pressure of end-tidal carbon dioxide (PETCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mechanical/structural abnormalities in LV pacing leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Mineral Density (BMD) of hip and spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood concentration of omega-3 and omega-6 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebrospinal fluid collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of infusion related reactions (IRRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of relative protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of lipid profile for plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reflective Total Nasal Symptom Score (rTNSS) Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in WOMAC Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Non-immunologic loss of transplanted islet mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OK-432 success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to symptomatic AF/AT/AFl lasting > 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Gastric Percentage Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Determination of T supressor cell (Treg cell) frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of ORI to Detect Drops in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of ORI to Detect Drops in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concordance of ORI to Detect Drops in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time above MIC of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Achieved Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: completeness of neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum soluble CD14 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and efficacy of the PrePex device
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial high rate/Automatic mode switch episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intra-operative surgery-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of the studied agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Related TEAEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Wounds With Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary patency (no stenosis >50%) of the Target Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Alleviation of chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Usefulness of the HIV Self-testing Infographic
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of Use of the HIV Self-testing Infographic
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with the HIV Self-testing Infographic
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Velocity of the right hand movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forces applied by the hand on the objects to be grasped
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Torques applied by the hand on the objects to be grasped
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Experienced Adverse Events That Led to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: MMSE Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sage test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concordance between MMSE and Sage test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to myasthenia gravis generalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy continuation beyond twelve weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: CIN2+/CIN3+/Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urea breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Venous occlusion plethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of HIV-1 and HIV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Total 24-hour urinary glucose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Quality of life in Alzheimer's Disease (QOL-AD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Inflammatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee OA pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wound measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in wound characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Response Rate Categorized by p63/p73 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response Outcome of Clostridium Difficile Infection Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Response Outcome of Failure or Unable to Evaluate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Moods and Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIV incident rate among adults 15 years and older
Endpoint domain: Mortality/survival
Primary endpoint: Sub-national prevalence of suppressed HIV viral load (<1,000 copies/mL) among adults 15 and older
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV prevalence of children ages 0-14
Endpoint domain: Mortality/survival
Primary endpoint: Severity of Autism-Spectrum Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Any Adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Onset of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Treatment-Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Favorable Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants who obtain technical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of thrombosis of the prosthetic branches, visceral arteries and replanted intercostal arteries
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of aneurysmal dilatation of visceral and replanted intercostal arteries
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with complete biochemical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumococcal serotype-specific antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With PD According to RECIST or Death
Endpoint domain: Mortality/survival
Primary endpoint: PFS in All Participants
Endpoint domain: Mortality/survival
Primary endpoint: Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of severe and very severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Length in months of drug survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants with Low Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Right ventricular myocardial velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 Month Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12 Month Smoking Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean nicotine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores on the Minnesota Nicotine Withdrawal Scale (MNWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy (PRR) of DSM265 or OZ439
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of OZ439 on P. Vivax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of DSM265 or OZ439 - Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal variation of serum hepcidin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Malignancy of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Activity of High-dose 3F8/GM-CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Inhibition from Baseline of interferon (IFN) Transcriptional Biomarkers at Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of SELENA SLEDAI score at indicated time points up to Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any adverse events (AEs) and any serious adverse events (SAEs) up to Week 16
Endpoint domain: Adverse events/effects
Primary endpoint: Trimethylamine N-oxide (TMAO) production capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of ICAM-
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentration of vWF Ag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Insulin Lispro AUC[0-10h]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in stone size and surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Expulsion of stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evaluation of clinical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taiwanese Geriatric Depression Scale (TGDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Groningen Activity Restriction Scale (GARS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Corrected Glucose Disposal Rate (cGDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS pain score relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of glottis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression (24 Item)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: metabolic measures of neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trauma recidivism after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of dermatofibrosarcoma protuberans
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of patients sent to xrays
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of breastfeeding duration
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of Cognitive Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time it takes subject to fall asleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Minutes of Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Arousals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stepping speed adjustment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variance in stepping speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 5-point Venham Anxiety Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in 5-point Venham Uncooperative Behavior Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vitamin B12 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in systolic and diastolic blood pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in proteinuria from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in GFR from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lower Extremity Motor Coordination Test (LEMOCOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of technical success or failure to complete initial procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in directional error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week Continuous Quit Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma total amino acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Blood C-reactive (CRP) Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intracranial Disease Overall Response Rate by RANO-BM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intracranial Disease Overall Response Rate by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in blood loss (in mLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of treatment-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in overall Scar-appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants who Achieve Prostate-specific Antigen (PSA) <=0.2 ng/mL Within a Year from Registration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in size of endometriomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell osmotic fragility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red blood cell deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red blood cell hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes